DNA X Financials
This page shows DNA X (SONM) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 8 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
External financing is supporting a business whose operating cash losses deepen while liabilities become almost entirely short-term.
In FY2025, operating cash flow of-$23.5M exceeded the net loss of-$20.7M in magnitude, so reported earnings understated the cash required by operations. That outflow was roughly five times FY2023’s-$4.1M , indicating a sharp deterioration in cash conversion rather than a one-year accounting effect.
Negative equity widened from
The current ratio fell from 0.7x in FY2024 to 0.6x in FY2025, while all FY2025 liabilities were current. This structure means near-term obligations exceed near-term assets, making the balance sheet’s pressure primarily a liquidity issue rather than simply long-term leverage.
Financial Health Signals
DNA X does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
DNA X passes 2 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 1 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass.
DNA X reported a net loss of $20.7M while operations used $23.5M of cash. With neither figure positive, the ratio between the two carries no quality signal.
DNA X reported an operating loss of $5.4M against $945K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
DNA X's EBITDA was -$1.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 342.0% from the prior year.
DNA X reported -$20.7M in net income in fiscal year 2025. This represents an increase of 38.6% from the prior year.
Not reported for fiscal year 2025.
Cash & Balance Sheet
DNA X held $1.3M in cash against $5.1M in long-term debt as of fiscal year 2025.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Margins & Returns
None of these metrics is reported for fiscal year 2025.
Capital Allocation
None of these metrics is reported for fiscal year 2025.
SONM Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | $16.2M+44.9% | $11.2M-33.1% | $16.7M+11.6% | $15.0M-0.3% | $15.0M |
| Cost of Revenue | N/A | N/A | N/A | $11.9M+51.1% | $7.8M-6.2% | $8.4M-55.0% | $18.6M+104.3% | $9.1M |
| Gross Profit | N/A | N/A | N/A | $1.8M+114.9% | $845K-89.9% | $8.4M+4666.1% | -$183K-104.3% | $4.2M |
| R&D Expenses | N/A | N/A | N/A | $181K-80.1% | $909K-44.3% | $1.6M-86.9% | $12.5M+1649.2% | $715K |
| SG&A Expenses | $1.3M-64.7% | $3.6M | N/A | $3.2M+115.0% | $1.5M+69.1% | $870K+118.0% | -$4.8M-269.8% | $2.8M |
| Operating Income | -$1.3M+64.7% | -$3.6M | N/A | -$4.0M-170.6% | -$1.5M-69.1% | -$870K-110.3% | $8.4M+455.0% | -$2.4M |
| Interest Expense | N/A | $131K | N/A | $339K+110.6% | $161K+126.8% | $71K | N/A | N/A |
| Income Tax | -$243K-109.6% | $2.5M | N/A | $90K-34.8% | $138K+4.5% | $132K+349.1% | -$53K-145.3% | $117K |
| Net Income | -$1.2M-119.7% | $6.3M | N/A | -$4.8M+36.4% | -$7.5M-1732.1% | $458K+102.1% | -$21.6M-760.4% | -$2.5M |
| EPS (Diluted) | -$0.92-118.4% | $5.01+153.1% | -$9.44-95.4% | -$4.83 | -$14.15 | $1.41 | -$4.55 | -$9.32 |
SONM Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $4.5M-6.6% | $4.8M-89.0% | $43.9M+9.1% | $40.2M+11.5% | $36.1M+0.3% | $36.0M-9.5% | $39.7M-19.1% | $49.1M |
| Current Assets | $2.9M-11.5% | $3.3M-88.6% | $28.9M-4.6% | $30.3M+11.7% | $27.1M+0.7% | $26.9M-16.3% | $32.2M-5.0% | $33.9M |
| Cash & Equivalents | $900K-24.7% | $1.2M-8.3% | $1.3M-39.0% | $2.1M+6.5% | $2.0M-5.2% | $2.1M-60.4% | $5.3M-41.0% | $9.1M |
| Inventory | N/A | N/A | N/A | $11.0M+11.1% | $9.9M+14.7% | $8.6M-18.8% | $10.6M-14.2% | $12.4M |
| Accounts Receivable | N/A | $57K | N/A | $3.5M+21.9% | $2.9M-40.8% | $4.8M+11.8% | $4.3M-17.2% | $5.2M |
| Total Liabilities | $5.7M+16.8% | $4.9M-90.3% | $50.6M+23.7% | $40.9M+9.4% | $37.4M+1.0% | $37.0M-18.5% | $45.4M+34.4% | $33.8M |
| Current Liabilities | $5.1M+19.2% | $4.3M-91.5% | $50.6M+30.3% | $38.9M+9.0% | $35.7M+2.8% | $34.7M-20.7% | $43.7M+35.9% | $32.2M |
| Long-Term Debt | N/A | $1.1M-78.8% | $5.1M+1926.0% | $250K-91.4% | $2.9M+415.2% | $566K | N/A | N/A |
| Total Equity | -$1.2M-25.3% | -$983K+87.6% | -$8.0M-1034.8% | -$701K+47.5% | -$1.3M-23.6% | -$1.1M+81.1% | -$5.7M-137.1% | $15.3M |
| Retained Earnings | -$298.9M-0.4% | -$297.6M+2.2% | -$304.3M-3.0% | -$295.4M-1.6% | -$290.6M-2.6% | -$283.1M+0.2% | -$283.6M-8.2% | -$262.0M |
Not reported in any period shown, so not listed: Goodwill.
SONM Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$2.0M+42.3% | -$3.5M-73.0% | -$2.0M+71.5% | -$7.0M-44.1% | -$4.9M+49.2% | -$9.6M-113.0% | -$4.5M-981.3% | -$417K |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | N/A | $8K-94.2% | $137K |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | -$4.5M-715.3% | -$554K |
| Investing Cash Flow | -$94K-102.8% | $3.4M | N/A | N/A | N/A | N/A | -$8K+94.2% | -$137K |
| Financing Cash Flow | N/A | N/A | $1.2M-83.7% | $7.2M+50.1% | $4.8M-25.2% | $6.4M+697.3% | $800K+5614.3% | $14K |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
SONM Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | 11.2%+3.7pp | 7.5%-42.4pp | 50.0%+51.2pp | -1.2%-29.4pp | 28.2% |
| Operating Margin | N/A | N/A | N/A | -24.6%-11.4pp | -13.2%-8.0pp | -5.2%-61.5pp | 56.3%+72.1pp | -15.8% |
| Net Margin | N/A | N/A | N/A | -29.3%+37.5pp | -66.8%-69.5pp | 2.7% | -144.3% | -16.7% |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -16.4% |
| Return on Assets | -27.6%-158.7pp | 131.1% | N/A | -11.8%+8.9pp | -20.7%-22.0pp | 1.3%+55.7pp | -54.4%-49.3pp | -5.1% |
| Current Ratio | 0.57-0.2x | 0.76+0.2x | 0.57-0.2x | 0.780.0x | 0.760.0x | 0.780.0x | 0.74-0.3x | 1.05 |
| Debt-to-Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 2.20 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | -30.1%-26.5pp | -3.7% |
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Net Margin.
Note: Shareholder equity is negative (-$8.0M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.57), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Where DNA X Ranks
Frequently Asked Questions
Is DNA X profitable?
No, DNA X (SONM) reported a net income of -$20.7M in fiscal year 2025.
What is DNA X's EBITDA?
DNA X (SONM) had EBITDA of -$1.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does DNA X have?
As of fiscal year 2025, DNA X (SONM) had $1.3M in cash and equivalents against $5.1M in long-term debt.
What is DNA X's operating cash flow?
DNA X (SONM) recorded an outflow of $23.5M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are DNA X's total assets?
DNA X (SONM) had $43.9M in total assets as of fiscal year 2025, including both current and long-term assets.
What is DNA X's current ratio?
DNA X (SONM) had a current ratio of 0.57 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.
What is DNA X's return on assets (ROA)?
DNA X (SONM) had a return on assets of -47.1% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
Why is DNA X's debt-to-equity ratio negative or not reported?
DNA X (SONM) has negative shareholder equity of -$8.0M as of fiscal year 2025, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is DNA X's Piotroski F-Score?
DNA X (SONM) has a Piotroski F-Score of 2 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are DNA X's earnings high quality?
DNA X (SONM) reported a net loss of $20.7M while operations used $23.5M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can DNA X cover its interest payments?
DNA X (SONM) reported an operating loss of $5.4M against $945K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.